Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-08-16
2011-08-16
Harris, Alana M (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S001000, C514S019300, C514S019400, C514S019500, C514S019800, C424S001110, C424S009100, C424S009200
Reexamination Certificate
active
07998934
ABSTRACT:
A method is described for detecting, visualizing, or treating cells, particularly cancerous cells, that express a uPA/uPAR complex. The method employs a PAI-2 conjugate molecule that comprises PAI-2 or a functional derivative, homologue, analogue, chemical equivalent or mimetic thereof, which PAI-2 is bound, linked, or otherwise associated with a toxin or label.
REFERENCES:
patent: 5124471 (1992-06-01), Gansow et al.
patent: 5422090 (1995-06-01), Stephens et al.
patent: 5444153 (1995-08-01), Goss et al.
patent: 5679350 (1997-10-01), Jankun et al.
patent: 6348185 (2002-02-01), Piwnica-Worms
Ye et al., “cDNA Cloning and Expression inEscherichia coliof a Plasminogen Activator Inhibitor from Human Placenta”, Journal of Biological Chemistry, vol. 262 (8): 3718-3725 (Mar. 15, 1987).
Antalis et al.; Cloning and expression of a cDNA coding for a human monocyte-derived plasminogen activator inhibitor, Proc. Natl. Acad. Sci. USA, vol. 85: 985-989 (Feb. 1988).
Jensen et al., Type-2 plasminogen-activator inhibitor is a substrate for trophoblast transglutaminase and Factor XIIIa; Transglutaminase-catalyzed cross-linking to cellular and extracellular structures, Eur. J. Biochem., 214: 141-146 (1993).
Saunders et al., Immunological Detection of Conformational Neoepitopes Associated with the Serpin Activity of Plasminogen Activator Inhibitor Type-2, Journal of Biological Chemistry, vol. 273 (18): 10965-10971 (May 1, 1998).
Ragno et al., Urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen-activator receptor in THP-1 cells, Eur. J. Biochem., 233: 514-519 (1995).
Schmitt et al., The urokinase plasminogen activator system as a novel target for tumor therapy, Fibrinolysis & Proteolysis, 14(2/3): 114-132 (2000).
Hermans et al., Inhibition of Acrosin by Serpins, A Suicide Substrate Mechanism, Biochemistry, 34: 3678-3685 (1995).
Jankova et al., Crystal Structure of the Complex of Plasminogen Activator Inhibitor 2 with a Peptide Mimicking the Reactive Center Loop, Journal of Biological Chemistry, vol. 276 (46): 43374-43382 (Nov. 16, 2001).
Andronicos et al., The human ENO1 gene product (recombinant human α-enolase) displays characteristics required for a plasminogen binding protein, Biochimica et Biophysica Acta 1337: 27-39 (1997).
Saunders et al., Interaction between the P14 Residue and Strand 2 of β-Sheet B is Critical for Reactive Center Loop Insertion in Plasminogen Activator Inhibitor-2, Journal of Biological Chemistry, vol. 276 (46): 43383-43389 (Nov. 16, 2001).
Jensen et al., Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells, Cell Regulation, vol. 1, 1043-1056 (Dec. 1990).
Hermanson, Bioconjugate Techniques, Bifunctional Chelating Agents and Radioimmunoconjugates, 365 (Academic Press 1996).
B.J. Allen et al., Alpha- and beta-emitting radiolanthanides in targeted cancer therapy: The potential role of terbium-149, Nuclear Medicine Communications, © 1996 Chapman and Hall Ltd., pp. 40-47, (1996).
B.J. Allen et al., “Can alpha-immunotherapy succeed where other systemic modalities have failed?”, Nuclear Medicine Communications (20), © 1999 Lippincott Williams & Wilkins, pp. 205-207, (1999).
Peter A. Andreasen et al., “The Urokinase-Type Plasminogen Activator System in Cancer Metastasis: a Review”, Int. J. Cancer: 72, © 1977 Wiley-Liss, Inc., pp. 1-22, (1977).
Duffy, Michael J. et al., “Urokinase Plasminogen Activator: A Prognostic Mqrker in Multiple in Multiple Types of Cancer”, Journal of Surgical Oncology (71), © 1999 Wiley-Liss, Inc., pp. 130-135, (1999).
Foekens, John A. et al. Plasminogen Activator Inhibitor-2: Prognostic Relevance in 1012 Patients with Primary Breast Cancer1, Cancer Research (55), pp. 1423-1427, (Apr. 1, 1995).
Hang, M.T.N., et al., “Pharmacokinetics and biodistribution of recombinant human plasminogen activator inhibitor type 2 (PAI-2) in control an dtumour xenograft-bearing mice”, Fibrinolysis & Proteolysis 12(3), © Harcurt Brace & Co., Ltd., pp. 145-154, (1998).
Jankun, Jerzy et al., “Antitumor Activity of the Type 1 Plasminogen Activator Inhibitor Cytotoxic Conjugate in Vitro1, ”Advances in Brief, PAI-2 Project, pp. 5829-5832.
Kennel, SJ et al., “Radioimmunotherapy of micrometastases in lung with vascular targeted213Bi”, British Journal of Cancer 80(1/2), © 1999 Cancer Research Campaign, pp. 175-184, (1999).
Kruithof, Egbert K.O., “Biological and Clinical Aspects of Plasminogen Activator Inhibitor Type 2”, Blood vol. 86, No. 11, © 1995 The American Society of Hematology, pp. 4007-4024, (Dec. 1, 1995).
Laug, Walter E. et al., Inhibition of Invasion of HT1080 Sarcoma Cells Expressing recombinant Plasminogen Activator Inhibitor 21,. Cancer Research 53, pp. 6051-6057, (Dec. 15, 1993).
Lloyd, E.L. et al., “Cell survival following multiple-track alpha particle irradiation”, Int. J. Radiat. Biol. vol. 35, No. 1, pp. 23-31, (1979).
Mueller, Barbara M. et al., “Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis inscid/scidmice”, Proc. Natl. Acad. Sci. USA 92, pp. 205-209, (Jan. 1995).
Pollanen, Jari et al., “Directed Plasminogen Activation at the Surface of Normal and Malignant Cells”, Advances in Cancer Research, vol. 57, © 1991 Academic Press, Inc., pp. 273-328.
Ranson, M. et al., “Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins”, © 1998 Cancer Research Campaign, pp. 1586-1597.
Schmitt, M. et al., “Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy”, Thrombosis and Haemostasis 78(1), © F.K. Schattauer Verlagsgesellschaft mbH, pp. 285-296, (1997).
Yang, Jia-Lin et al., “Urokinase-Type Plasminogen Activator and its Receptor in Cololrectal Cancer: Independent Prognostic Factors of Metastasis and Cancer-Specific Survival and Potential Therapeutic Targets”, Int. J. Cancer (Pred. Oncol.) 89, pp. 431-439, (2000).
B.J. Allen et al., “In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers”, Critical Reviews in Oncology/Hematology, Elsevier Science Ireland Ltd., Limerick, Ireland, vol. 39, No. 1-2, Jul. 2001, pp. 139-146.
B.J. Allen et al., “Targeted alpha therapy: Evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer”, Australasian Radiology, Blackwell Science Ltd., AU, vol. 43, 1999, pp. 480-486.
Jean Maublant, “Scintigraphic imaging of breast tumors”, European Journal of Radiology, Ireland Jan. 1, 1997, vol. 24, No. 1/1997 , pp. 2-10.
European Search Report for European Application No. 0 190 7246, Mar. 31, 2004.
Lazar, et al., Transforming Growth Factor Alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, Molecular and Cellular 8(3): 1247-1252, Mar. 1988.
Tsatas et al., Tissue-Specific Expression of the Relaxed Conformation of Plasminogen Activator Inhibitor-2 and Low-Density Lipoprotein Receptor-Related Protein in Human Term Gestational Tissues. The Journal of Histochemistry and Cytochemistry 45(12): 1593-1602, 1997.
Conese et al., Urokinase/Urokinase Receptor System: Internalization/Degradation of Urokinase-Serpin Complexes: Mechanism and Regulation, Biol. Chem. Hoppe-Seyler 376: 143-155, Mar. 1995.
Andreasen et al., “The Urokinase-Type Plasminogen Activator System in Cancer Metastasis: A Review” Int. J. Cancer, 72: 1-22 (1997) © Wiley-Liss, Inc.
Allen Barry John
Bunn Clive Leighton
Ranson Marie
Foley & Lardner LLP
Harris Alana M
Medical Scitec Australia Pty Ltd.
PAI-2 Pty Limited
University of Wollongong
LandOfFree
PAI-2 conjugates for the treatment and imaging of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PAI-2 conjugates for the treatment and imaging of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PAI-2 conjugates for the treatment and imaging of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2701974